Ipilimumab vs Peginterferon Alfa-2A
Ipilimumab vs Peginterferon Alfa-2A: Overview
This comparison examines the pharmacological differences between Ipilimumab and Peginterferon Alfa-2A.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days.
Chemical Properties
Type: Ipilimumab — Antibody; Peginterferon Alfa-2A — Protein.